Compare MBBC & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | KYNB |
|---|---|---|
| Founded | 1902 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 31.9M |
| IPO Year | N/A | N/A |
| Metric | MBBC | KYNB |
|---|---|---|
| Price | $13.25 | $7.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.1K | ★ 30.9K |
| Earning Date | 02-11-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.28 | ★ 53.38 |
| Revenue | $7,936,063.00 | ★ $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.79 | ★ $0.14 |
| Revenue Growth | ★ 21.07 | N/A |
| 52 Week Low | $9.34 | $4.85 |
| 52 Week High | $13.75 | $21.94 |
| Indicator | MBBC | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 36.71 |
| Support Level | $12.75 | $7.32 |
| Resistance Level | $13.75 | $8.25 |
| Average True Range (ATR) | 0.15 | 0.67 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 65.99 | 15.80 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.